A conserved degron containing an amphipathic helix regulates the cholesterol-mediated turnover of human squalene monooxygenase, a rate-limiting enzyme in cholesterol synthesis

被引:46
|
作者
Chua, Ngee Kiat [1 ]
Howe, Vicky [1 ]
Jatana, Nidhi [2 ]
Thukral, Lipi [2 ]
Brown, Andrew J. [1 ]
机构
[1] Univ New South Wales, Sch Biotechnol & Biomol Sci, Biol Sci Bldg D26, Sydney, NSW 2052, Australia
[2] CSIR, Inst Genom & Integrat Biol, Mathura Rd, New Delhi 110020, India
基金
澳大利亚研究理事会; 英国医学研究理事会;
关键词
cholesterol; cholesterol regulation; endoplasmic reticulum (ER); membrane protein; protein degradation; degron; squalene monooxygenase; UBIQUITIN-PROTEASOME SYSTEM; NUCLEAR-QUALITY CONTROL; ENDOPLASMIC-RETICULUM; WEB SERVER; HEDGEHOG ACYLTRANSFERASE; DEGRADATION SIGNALS; DISORDERED REGION; FORCE-FIELD; PROTEIN; MEMBRANE;
D O I
10.1074/jbc.M117.794230
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesterol biosynthesis in the endoplasmic reticulum (ER) is tightly controlled by multiple mechanisms to regulate cellular cholesterol levels. Squalene monooxygenase (SM) is the second rate-limiting enzyme in cholesterol biosynthesis and is regulated both transcriptionally and post-translationally. SM undergoes cholesterol-dependent proteasomal degradation when cholesterol is in excess. The first 100 amino acids of SM (designated SM N100) are necessary for this degradative process and represent the shortest cholesterol-regulated degron identified to date. However, the fundamental intrinsic characteristics of this degron remain unknown. In this study, we performed a series of deletions, point mutations, and domain swaps to identify a 12-residue region (residues Gln-62-Leu-73), required for SM cholesterol-mediated turnover. Molecular dynamics and circular dichroism revealed an amphipathic helix within this 12-residue region. Moreover, 70% of the variation in cholesterol regulation was dependent on the hydrophobicity of this region. Of note, the earliest known Doa10 yeast degron, Deg1, also contains an amphipathic helix and exhibits 42% amino acid similarity with SM N100. Mutating SM residues Phe-35/Ser-37/Leu-65/Ile-69 into alanine, based on the key residues in Deg1, blunted SM cholesterol-mediated turnover. Taken together, our results support a model whereby the amphipathic helix in SM N100 attaches reversibly to the ER membrane depending on cholesterol levels; with excess, the helix is ejected and unravels, exposing a hydrophobic patch, which then serves as a degradation signal. Our findings shed new light on the regulation of a key cholesterol synthesis enzyme, highlighting the conservation of critical degron features from yeast to humans.
引用
收藏
页码:19959 / 19973
页数:15
相关论文
共 4 条
  • [1] A Conserved Degron Containing an Amphipathic Helix Regulates the Cholesterol-Mediated Turnover of Human Squalene Monooxygenase, a Rate-Limiting Enzyme in Cholesterol Synthesis
    Chua, Ngee Kiat
    Howe, Vicky
    Jatana, Nidhi
    Thukral, Lipi
    Brown, Andrew J.
    FASEB JOURNAL, 2018, 32 (01):
  • [2] Posttranslational Regulation of HMG CoA Reductase, the Rate-Limiting Enzyme in Synthesis of Cholesterol
    Schumacher, Marc M.
    DeBose-Boyd, Russell A.
    ANNUAL REVIEW OF BIOCHEMISTRY, VOL 90, 2021, 2021, 90 : 659 - 679
  • [3] Desvenlafaxine prevents white matter injury and improves the decreased phosphorylation of the rate-limiting enzyme of cholesterol synthesis in a chronic mouse model of depression
    Wang, Junhui
    Qiao, Jinping
    Zhang, Yanbo
    Wang, Hongxing
    Zhu, Shenghua
    Zhang, Handi
    Hartle, Kelly
    Guo, Huining
    Guo, Wei
    He, Jue
    Kong, Jiming
    Huang, Qingjun
    Li, Xin-Min
    JOURNAL OF NEUROCHEMISTRY, 2014, 131 (02) : 229 - 238
  • [4] Desvenlafaxine prevents white matter injury and improves the decreased phosphorylation of rate-limiting enzyme of cholesterol synthesis in a chronic mouse model of depression.
    Zhang, Yanbo
    Hartle, Kelly
    Huang, Qingjun
    Kong, Jiming
    Li, Xin-Min
    Wang, Hongxing
    Wang, Juijui
    Zhang, Handi
    Zhu, Shenghua
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 86 - 87